Clinical psychology review

Ketamine combined with therapy for mental health problems: history and review

Updated

Abstract

A total of 64 articles were included in a systematic review assessing ketamine-assisted psychotherapy across various psychiatric disorders.

  • The review analyzed 72 studies, with only 11 identified as randomized controlled trials (RCTs), indicating a scarcity of rigorous evidence.
  • Ketamine-assisted psychotherapy may show transdiagnostic effectiveness for conditions such as major depressive disorder and posttraumatic stress disorder.
  • KAP appears to enhance treatment engagement and symptom reduction compared to psychotherapy alone.
  • Two studies that randomized psychotherapy alongside ketamine treatment did not demonstrate significant additive effects from psychotherapy.
  • Methodological differences and the low number of trials using psychotherapy control groups limit the ability to draw definitive conclusions.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest C.S. received payment or honoraria from the European Monitoring Centre for Drugs and Drug Addiction and was supported for attending multi-stakeholder workshop by EMA. The funders had no role in the preparation, review or approval of the manuscript, nor in the decision to submit the manuscript for publication. A.J.O.-M. was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd. (2019–2020), of a trial of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd. (EudraCT number 2017–003288-36), and of a trial of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd. (EudraCT NUMBER: 2019–002992–33). He is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests. In the past 3 years, he received payment, honoraria, support for attending meetings and participated in advisory boards from MSD, Neurolite AG, Janssen, Angelini and the European Monitoring Centre for Drugs and Drug Addiction. He is Vice-President of the Portuguese Society for Psychiatry and Mental Health and Head of the Psychiatry Working Group for the National Board of Medical Examination (GPNA) at the Portuguese Medical Association and Portuguese Ministry of Health. R.S. has received research funding for two randomized clinical trials with generic oral esketamine from the Netherlands Organisation for Health Research & Development and the National Health Care Institute, a speaker's fee and an investigator-initiated research grant from Janssen Pharmaceuticals, and consultancy fees from Clexio Biosciences, GH Research, Beckley PsyTech, and QPS. J.K. has received speakers fee from Janssen-Cilag. J.J.B., C.S., A.J.O.-M. and R.A.S. are supported by PsyPal (HORIZON-HLTH-2023DISEASE-03, ID101137378) funded under the EU's research and innovation program. The other authors declare to have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free